Tag: high-frequency spinal cord stimulation
Nevro announces “profound improvements” in non-surgical refractory back pain patients treated...
Nevro Corporation has announced the publication of new 24-month data from the SENZA-NSRBP multicentre randomised controlled trial (RCT) in the Journal of Neurosurgery: Spine. The...
Two-year data indicate long-term effectiveness of Nevro’s SCS therapy in painful...
Nevro Corporation recently announced the publication of 24-month data from the SENZA painful diabetic neuropathy (PDN) randomised controlled trial (RCT)—the largest RCT to evaluate...
High-frequency spinal cord stimulation may be associated with “significant decrease” in...
High-frequency spinal cord stimulation (HF-SCS) for treating chronic refractory low back pain (CRLBP) may be associated with a significant decrease in total healthcare costs,...
Nevro announces positive coverage updates for treatment of painful diabetic neuropathy...
Nevro Corporation has announced that US health plan Aetna has updated its spinal cord stimulation (SCS) coverage policy to explicitly cover painful diabetic neuropathy...
High-frequency SCS demonstrates “substantial improvement” in health-related quality of life outcomes
Nevro Corporation has announced that the complete 12-month results from the SENZA-PDN randomised controlled trial (RCT), including health-related quality of life outcomes in patients with...
High-frequency SCS drives impactful outcomes for non-surgical refractory back pain patients
Following the recent introduction of key data supporting the use of high-frequency spinal cord stimulation (SCS) in the treatment of non-surgical refractory back pain...
Nevro announces publication of 12-month data on high-frequency SCS for non-surgical...
Nevro Corporation has announced online publication of 12-month data from the SENZA-NSRBP randomised controlled trial (RCT) in Journal of Neurosurgery: Spine. These data show that...
NANS 2022: New 18-month data show durability of high-frequency SCS for...
This year’s North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) saw 18-month data from SENZA-PDN—a randomised controlled trial (RCT) evaluating the...
Study shows “major energy savings” can be achieved in spinal cord...
The results of the HALO (High and low frequency options) study, which are published online in the scientific journal Neuromodulation: Technology at the Neural...
Prospective study shows good efficacy with high-frequency spinal cord stimulation in...
A study published in the journal Neuromodulation reports good efficacy with high-frequency spinal cord stimulation with notable reductions on the numerical rating scale back...
